Clinical Trial Update: Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting the efficacy and safety of quetiapine fumarate sustained release (SEROQUEL SR) for major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Seroquel SR (quetiapine extended-release)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED